复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600196 复星医药

交易中 11-22 13:15:56

{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":26.73,"timestamp":1732252556000,"preClose":27.29,"halted":0,"volume":11427400,"delay":0,"floatShares":2118000000,"shares":2671000000,"eps":0.7914,"marketStatus":"交易中","marketStatusCode":2,"change":-0.56,"latestTime":"11-22 13:15:56","open":27.26,"high":27.28,"low":26.65,"amount":308000000,"amplitude":0.0231,"askPrice":26.73,"askSize":26,"bidPrice":26.72,"bidSize":43,"shortable":0,"etf":0,"ttmEps":0.7914,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1732258800000},"adr":0,"adjPreClose":27.29,"symbolType":"stock","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":30.02,"lowLimit":24.56,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2671326465,"pbRate":1.54,"roa":"--","roe":"4.32%","epsLYR":0.89,"committee":0.285808,"marketValue":71405000000,"floatMarketCap":56627000000,"peRate":33.775587,"changeRate":-0.0205,"turnoverRate":0.0054,"status":1},"requestUrl":"/m/hq/s/600196/wiki","defaultTab":"wiki","newsList":[{"id":"2484008839","title":"九源基因(02566.HK)预计11月28日上市 引入复星医药等多家基石","url":"https://stock-news.laohu8.com/highlight/detail?id=2484008839","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484008839?lang=zh_cn&edition=full","pubTime":"2024-11-20 07:03","pubTimestamp":1732057406,"startTime":"0","endTime":"0","summary":"格隆汇11月20日丨九源基因发布公告，公司拟全球发售4539.88万股H股，中国香港发售股份454万股，国际发售股份4085.88万股；2024年11月20日至11月25日招股，预期定价日为11月26日；发售价将为每股发售股份11.48-12.56港元，每手买卖单位为200股；华泰国际为独家保荐人；预期股份将于2024年11月28日开始在联交所买卖。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120070335abd044b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120070335abd044b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0096","BK0028","BK0175","BK0188","600196","BK0060","BK0183","BK0239","BK0196","02196","BK0187","BK0012"],"gpt_icon":0},{"id":"2484998217","title":"券商看好复星国际战略聚焦、多元业务稳健，给予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2484998217","media":"中金在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484998217?lang=zh_cn&edition=full","pubTime":"2024-11-19 15:10","pubTimestamp":1732000208,"startTime":"0","endTime":"0","summary":"近日，东北证券发表研究报告，认为复星国际在“科创+全球化布局”双轮驱动下，战略定位清晰、四大板块业务稳健，此外还通过优化资产配置，现金流稳步改善。东北证券对复星的未来发展前景持乐观态度，并给予“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119152331a24502da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119152331a24502da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00656","600196","02196"],"gpt_icon":0},{"id":"2483391481","title":"复星医药于北京成立医疗科技公司，含AI相关业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2483391481","media":"企查查","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483391481?lang=zh_cn&edition=full","pubTime":"2024-11-15 10:30","pubTimestamp":1731637829,"startTime":"0","endTime":"0","summary":"企查查APP显示，近日，北京知星达医疗科技有限公司成立，法定代表人为刘毅，注册资本为96万元人民币，经营范围包含：专业设计服务；图文设计制作；计算机系统服务；人工智能基础软件开发；软件开发；人工智能应用软件开发等。企查查股权穿透显示，该公司由复星医药（600196）间接全资持股。（责任编辑：董萍萍 ）【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115120548a2398f25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115120548a2398f25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0187","BK0196","BK0012","BK0183","BK0188","159891","BK0175","BK0096","BK0239","600196","BK0060"],"gpt_icon":0},{"id":"2483988827","title":"帕金森药物上新，由复星医药引入","url":"https://stock-news.laohu8.com/highlight/detail?id=2483988827","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483988827?lang=zh_cn&edition=full","pubTime":"2024-11-14 17:53","pubTimestamp":1731578026,"startTime":"0","endTime":"0","summary":"帕金森用药上新据头豹研究院，按药物作用机制划分，帕金森病药物主要有6大类，具体包括抗胆碱能药物、促多巴胺释放药物、多巴胺替代药物、多巴胺受体激动剂、B型单胺氧化酶抑制剂、COMT抑制剂。2018年，复星医药与葡萄牙BIAL公司达成协议，引进该创新药。抗帕金森病药物指用于治疗帕金森病引起的静止震颤、肌肉强直、运动迟缓和共济失调等症状的一类药物。这是全球首个治疗帕金森病的长效缓释微球制剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114184233abc0d139&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114184233abc0d139&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","BK0183","BK0187","BK0188","600196","BK0175","BK0096","BK0060","BK0028","BK0196","02196","BK0239"],"gpt_icon":0},{"id":"2482275300","title":"复星医药11月11日收涨0.07% 主力资金逆市抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2482275300","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482275300?lang=zh_cn&edition=full","pubTime":"2024-11-11 15:19","pubTimestamp":1731309580,"startTime":"0","endTime":"0","summary":"11月11日, 复星医药股价涨0.07%，报收27.48元，成交金额7.53亿元，换手率1.30%，振幅2.18%，量比1.21。复星医药今日主力资金净流出6075万元，上一交易日主力净流出1.22亿元，今日环比减少50.12%。该股近5个交易日上涨2.38%，主力资金累计净流出2.12亿元；近20日主力资金累计净流出3.56亿元，其中净流出天数为14日。净流出前三个股分别为恒瑞医药、华东医药、复星医药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111152753a22bb549&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111152753a22bb549&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0183","BK0196","BK0012","600196","BK0096","BK0175","BK0060","BK0188","BK0028","BK0187","BK0239"],"gpt_icon":0},{"id":"2481017017","title":"复星医药（600196）股东上海复星高科技(集团)有限公司质押740万股，占总股本0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481017017","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481017017?lang=zh_cn&edition=full","pubTime":"2024-11-08 21:19","pubTimestamp":1731071996,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药11月8日公开信息显示，股东上海复星高科技(集团)有限公司向中国工商银行股份有限公司上海市长宁支行合计质押740.0万股，占总股本0.28%。质押详情见下表：截止本公告日，股东上海复星高科技(集团)有限公司已累计质押股份6.54亿股，占其持股总数的73.47%。复星医药主营业务：制药、医疗器械与医学诊断、医疗健康服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110800041279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","BK0012","BK1515","BK0060","BK0096","02196","BK0187","600196","BK1191","BK1593","BK0028","BK0239","BK0183","BK0175"],"gpt_icon":0},{"id":"2481126864","title":"复星医药(02196)控股股东复星高科技质押740万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2481126864","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481126864?lang=zh_cn&edition=full","pubTime":"2024-11-08 17:53","pubTimestamp":1731059607,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)公布，公司于 2024 年 11 月 8 日接到控股股东上海复星高科技(集团)有限公司(以下简称“复星高科技”)的通知，其已将所持有公司的部分 A 股股份办理质押手续。2024 年 11 月 7 日，复星高科技质押740万股股份予中国工商银行股份有限公司上海市长宁支行。本次办理股份质押后，复星高科技累计质押本公司股份(均为 A 股)数量为6.538亿股，约占截至 2024 年 11 月 7 日公司股份总数的 24.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0028","BK0183","BK0188","BK0196","BK0096","BK0187","BK0239","BK0012","BK1515","BK1191","600196","BK1593","02196","BK0060"],"gpt_icon":0},{"id":"2481145606","title":"复星医药11月08日主力大幅流出1.22亿元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2481145606","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481145606?lang=zh_cn&edition=full","pubTime":"2024-11-08 15:18","pubTimestamp":1731050285,"startTime":"0","endTime":"0","summary":"11月08日, 复星医药股价跌0.33%，报收27.46元，成交金额7.95亿元，换手率1.36%，振幅2.21%，量比1.37。复星医药今日主力资金净流出1.22亿元，上一交易日主力净流入10万元。该股近5个交易日上涨3.58%，主力资金累计净流出1.43亿元；近20日主力资金累计净流出2.97亿元，其中净流出天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108152715a2233278&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108152715a2233278&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","BK0028","BK0187","BK0196","BK0188","BK0060","BK0239","BK0183","BK0175","600196","BK0096"],"gpt_icon":0},{"id":"2481167598","title":"南向资金11月7日净买入复星医药28.55万股 连续7日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2481167598","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481167598?lang=zh_cn&edition=full","pubTime":"2024-11-08 09:30","pubTimestamp":1731029416,"startTime":"0","endTime":"0","summary":"11月7日, 南向资金增持复星医药28.55万股，连续7日增持。截止当日收盘，港股通共持有复星医药30350.41万股，占流通股54.98%。复星医药近5个交易日上涨5.14%，港股通累计增持284.60万股；近20个交易日上涨1.43%，港股通累计增持1159.80万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108093157ababa39c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108093157ababa39c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0060","BK0183","BK0239","600196","BK0096","BK0012","BK0187","BK0196","BK0028","BK0188","02196","BK0175"],"gpt_icon":0},{"id":"2481695604","title":"南向资金11月5日净买入复星医药13.55万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2481695604","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481695604?lang=zh_cn&edition=full","pubTime":"2024-11-06 09:30","pubTimestamp":1730856615,"startTime":"0","endTime":"0","summary":"11月5日, 南向资金增持复星医药13.55万股，连续5日增持。截止当日收盘，港股通共持有复星医药30280.46万股，占流通股54.85%。复星医药近5个交易日上涨5.35%，港股通累计增持360.65万股；近20个交易日下跌20.99%，港股通累计增持933.65万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106093154aba36c34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106093154aba36c34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600196","02196","BK1191","BK1593","BK1515"],"gpt_icon":0},{"id":"2481177574","title":"复星七赴进博 郭广昌：坚信中国高水平开放是时代机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2481177574","media":"凤凰网财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481177574?lang=zh_cn&edition=full","pubTime":"2024-11-05 19:23","pubTimestamp":1730805789,"startTime":"0","endTime":"0","summary":"11月5日，第七届中国国际进口博览会在国家会展中心（上海）开幕。2019年，Ion在进博会一经亮相就吸引了观众眼球。肺癌被称为癌症“头号杀手”，2022年中国新发肺癌高达106.06万例。肺癌患者5年生存率仅为19.7%，支气管镜检查是肺癌早期诊断的重要手段。截至今年第三季度，全球已安装了736套Ion，实施了超过15万例Ion手术。复星积极响应这一临床未满足的需求。今年，复星重点展示了奕凯达在淋巴瘤治疗领域“可及可愈”的最新进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105192130a21854a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105192130a21854a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","600196","BK1230","00656","BK1515","BK1191","02196"],"gpt_icon":0},{"id":"2480370825","title":"复星医药(02196.HK)两子公司药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2480370825","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480370825?lang=zh_cn&edition=full","pubTime":"2024-11-04 17:58","pubTimestamp":1730714280,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，旗下两家子公司分别各有一药物获得国家药品监督管理局受理其药品注册申请。两款药物都是集团自主研发的化学药品，一款用于治疗敏感细菌引起的炎症，另一款则用作治疗白血病。公司表示，截至9月针对两款新药物的累计研发投资分别为133万及257万元人民币。(vc/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-04 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220221174702240_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220221174702240_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1393971/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0188","BK0196","BK0012","BK1515","BK0060","BK0096","02196","BK0187","600196","BK1191","BK1593","BK0028","BK0239","BK0183","BK0175"],"gpt_icon":0},{"id":"2480375690","title":"复星医药(600196.SH)子公司两款新药获药品注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2480375690","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480375690?lang=zh_cn&edition=full","pubTime":"2024-11-04 16:35","pubTimestamp":1730709309,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，公司控股子公司重庆药友制药有限责任公司的左氧氟沙星注射液、控股子公司吉斯美(武汉)制药有限公司的阿糖胞苷注射液的药品注册申请分别获国家药品监督管理局受理。根据IQVIACHPA最新数据，2023年，已于中国境内获批上市的左氧氟沙星注射剂的销售额约为人民币24.70亿元、阿糖胞苷注射剂的销售额约为人民币2.65亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0028","600196","BK1593","BK0096","BK0175","BK0012","BK0183","BK1515","BK0188","BK0187","02196","BK1191","BK0060","BK0239"],"gpt_icon":0},{"id":"2480375699","title":"复星医药：控股子公司获药品注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2480375699","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480375699?lang=zh_cn&edition=full","pubTime":"2024-11-04 16:34","pubTimestamp":1730709249,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["01477","BK1191","BK0012","BK0028","BK0187","BK0196","BK1574","BK0188","BK1593","BK1515","BK0060","BK0239","BK0183","BK0175","600196","BK0096","02196"],"gpt_icon":0},{"id":"2480317935","title":"南向资金11月1日净买入复星医药133.10万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2480317935","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480317935?lang=zh_cn&edition=full","pubTime":"2024-11-04 09:30","pubTimestamp":1730683816,"startTime":"0","endTime":"0","summary":"11月1日, 南向资金增持复星医药133.10万股，连续3日增持。截止当日收盘，港股通共持有复星医药30198.91万股，占流通股54.71%。复星医药近5个交易日上涨1.37%，港股通累计增持226.85万股；近20个交易日下跌4.50%，港股通累计增持579.05万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104093152ab9c3745&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"d687eec3b8c9c2cb79b216c38e84ebbe","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104093152ab9c3745&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0196","BK0012","BK0060","BK0096","02196","BK0187","600196","BK0028","BK0239","BK0183","BK0175"],"gpt_icon":0},{"id":"2480279367","title":"中航证券：给予复星医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480279367","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480279367?lang=zh_cn&edition=full","pubTime":"2024-11-03 23:36","pubTimestamp":1730648175,"startTime":"0","endTime":"0","summary":"中航证券有限公司李蔚近期对复星医药进行研究并发布了研究报告《经营现金流优化，创新聚焦》，本报告对复星医药给出买入评级，当前股价为26.51元。　　2024年9月13日，公司控股子公司复星医药产业与KitePharma、复星凯特共同签订《股权转让协议》，约定复星医药产业将增持复星凯特50%的股权。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级3家，增持评级2家；过去90天内机构目标均价为31.0。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110300001926.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","02196","600196"],"gpt_icon":0},{"id":"2480065120","title":"复星医药：洞庭药业的该款产品未中选国家第八次集采。有关集采中选产品情况，可参见公司定期报告的汇总披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2480065120","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480065120?lang=zh_cn&edition=full","pubTime":"2024-11-01 19:00","pubTimestamp":1730458818,"startTime":"0","endTime":"0","summary":"有关公司主要治疗领域核心产品的收入、成本及毛利率情况，可参考公司发布的定期报告。洞庭药业的该款产品未中选国家第八次集采。有关集采中选产品情况，可参见公司定期报告的汇总披露。截至目前，题述临床批件对应的III期临床试验已完成、尚未提交上市申请。有关公司主要在研品种的临床上市进展，可留意公司发布的临时公告和定期报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100039479.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","BK0060","BK0183","BK1191","BK1593","BK0012","BK0096","BK1515","BK0175","BK0028","BK0188","BK0196","02196","BK0187","BK0239"],"gpt_icon":0},{"id":"2480949074","title":"复星医药(02196)11月1日斥资492.32万港元回购33万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2480949074","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480949074?lang=zh_cn&edition=full","pubTime":"2024-11-01 17:26","pubTimestamp":1730453185,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，于2024年11月1日斥资492.32万港元回购股份33万股，每股回购价格为14.8-14.98港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1205670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK0012","BK0188","BK0060","BK1593","BK0175","BK0196","BK0096","BK0239","BK0028","BK0183","BK0187","BK1191","600196","02196"],"gpt_icon":0},{"id":"2480741420","title":"复星医药2024前三季度归母扣非净利润同比增24.58%，多款创新药取得进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2480741420","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480741420?lang=zh_cn&edition=full","pubTime":"2024-11-01 16:55","pubTimestamp":1730451351,"startTime":"0","endTime":"0","summary":"近日，复星医药发布2024年三季报，报告显示，今年前三季度实现营业收入309.12亿元，同比增长0.69%，其中，不含新冠相关产品，营业收入同比增长约5.74%；实现归母扣非净利润18.36亿元，同比增长24.58%。2024年前三季度，其研发投入达39.15亿元，其中研发费用26.48亿元，占营业收入的8.57%。在自研产品方面，复星医药多个创新药取得重要进展。在H股方面，2024年前三季度，复星医药已斥资约6690万港元，回购547.15万股H股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101170920a207e66f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101170920a207e66f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600196","159992"],"gpt_icon":0},{"id":"2480027046","title":"复星医药11月01日遭主力抛售4637万元 环比增加6166.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480027046","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480027046?lang=zh_cn&edition=full","pubTime":"2024-11-01 15:17","pubTimestamp":1730445460,"startTime":"0","endTime":"0","summary":"11月01日, 复星医药股价跌0.34%，报收26.51元，成交金额5.43亿元，换手率0.96%，振幅1.80%，量比0.82。复星医药今日主力资金净流出4637万元，上一交易日主力净流出74万元，今日环比增加6166.22%。该股近5个交易日上涨1.77%，主力资金累计净流出4167万元；近20日主力资金累计净流出2.00亿元，其中净流出天数为15日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101152218ab90ab97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101152218ab90ab97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0175","BK0028","BK0183","BK0188","BK0196","BK0096","BK0187","BK0239","BK0012","600196","BK0060"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","stockEarnings":[{"period":"1week","weight":0.0085},{"period":"1month","weight":0.0569},{"period":"3month","weight":0.2183},{"period":"6month","weight":0.1951},{"period":"1year","weight":-0.0189},{"period":"ytd","weight":0.1029}],"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"267132万元","compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.1808},{"period":"6month","weight":0.0911},{"period":"1year","weight":0.1074},{"period":"ytd","weight":0.1329}],"survey":"　　上海复星医药(集团)股份有限公司主营业务是制药、医疗器械、医学诊断、医疗健康服务。主要产品为心血管系统疾病治疗领域核心产品、中枢神经系统疾病治疗领域核心产品、血液系统疾病治疗领域核心产品、代谢及消化系统疾病治疗领域核心产品、抗感染疾病治疗领域核心产品、抗肿瘤治疗领域核心产品、原料药和中间体核心产品。根据中华人民共和国工信部中国医药工业信息中心颁布的2018年度中国医药工业百强企业榜单，本集团位列第7。由米内研究院主办的“中国医药工业百强系列榜单”，本集团成功入选“2022年度中国化药企业TOP100排行榜”，位列中国化药企业百强榜第6位；根据IQVIA统计，2023年第一季度本集团的医院用处方药销售收入位列全国第12位；根据全球医药智库信息平台InformaPharmaIntelligence发布的《2023年医药研发趋势年度分析》白皮书，本集团再次入选“全球医药企业研发管线规模Top25”。","serverTime":1732252560125,"listedPrice":7.15,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,600196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}